Skip to main content

Lumos Pharma to Participate in Upcoming Investor Conferences

Written by Customer Service on . Posted in Public Companies.

AUSTIN, Texas, Aug. 27, 2020 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in September:• H.C. Wainwright 22nd Annual Global Investment Conference – September 14-16, 2020Lumos Pharma is scheduled to present Monday, September 14th, at 4:30PM ETManagement will be available for virtual one-on-one meetings September 14th – 16th• Cantor Virtual Global Healthcare Conference – September 15-17, 2020Lumos Pharma is scheduled to present Thursday, September 17th, at 8:40AM ETManagement will be available for virtual one-on-one meetings September 17th throughout the dayPlease contact your HC Wainwright and Cantor Fitzgerald sales representatives to participate in their investor conferences and to schedule a virtual one-on-one meeting with our management team. Live webcasts of each presentation will be available on the Company’s website in the “Investors & Media” section under “Events and Presentations.” An archived edition of the presentation will be available on the Company’s website later in the day on each day Lumos Pharma presents.About Lumos PharmaLumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit www.lumos-pharma.com.Investor & Media Contact:Lisa Miller
Lumos Pharma Investor Relations
512-648-3757
ir@lumos-pharma.comSource: Lumos Pharma, Inc.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.